Bristol Myers Squibb must face USD 6.4 billion lawsuit over delayed cancer drug Ruchika Sharma25 Jun 2022 3:30 PM ISTThe case arose from the company's agreement to pay Celgene shareholders holding "contingent value rights" an extra $9 per share in cash if it won U.S....
USFDA nod to Alembic Pharma cancer drug Dasatinib Ruchika Sharma10 Jun 2022 12:58 PM ISTVadodara: Drugmaker, Alembic Pharmaceuticals Limited, today announced that the company has received tentative approval from the US Food & Drug...
Bristol Myers Squibb withdraws supplemental biologics license application for Reblozyl for Non-transfusion Dependent (NTD) Beta Thalassemia Ruchika Sharma5 Jun 2022 5:00 PM ISTReblozyl, a first-in-class therapeutic option, is currently approved in the United States, European Union and Canada to address transfusion-dependent...
Bristol Myers Squibb to acquire Turning Point Therapeutics for USD 76.00 per share Ruchika Sharma5 Jun 2022 9:30 AM ISTNew York: Bristol Myers Squibb and Turning Point Therapeutics, Inc. have announced a definitive merger agreement under which Bristol Myers...
Bristol Myers Opdivo fails to meet primary endpoint in CheckMate -901 trial Ruchika Sharma19 May 2022 10:15 AM ISTUrothelial carcinoma, which most frequently begins in the cells that line the inside of the bladder, accounts for approximately 90% of bladder cancer...
Bristol Myers Squibb to sell its East Syracuse facility to LOTTE Ruchika Sharma15 May 2022 10:15 AM ISTFollowing the closing of the transaction, LOTTE, under a newly-established CDMO relationship, will manufacture product for Bristol Myers Squibb from...
Bristol Myers Squibb gets USFDA nod for obstructive hypertrophic cardiomyopathy drug Camzyos Ruchika Sharma1 May 2022 10:30 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (USFDA) has approved Camzyos (mavacamten, 2.5 mg, 5...
Bristol Myers Squibb, Nektar halt Bempegaldesleukin, Opdivo cocktail trials for cancer treatment Ruchika Sharma16 April 2022 2:57 PM ISTPrinceton: Nektar Therapeutics and Bristol Myers Squibb have announced that based on results from pre-planned analyses of two...
Roche, Bristol Myers Squibb ink pact to advance personalised healthcare through digital pathology solutions Ruchika Sharma28 March 2022 10:00 AM ISTData from both projects will be used to aid in cancer diagnosis and to advance personalised healthcare treatment options, with the aim of improving...
Bristol Myers gets USFDA approval for First LAG-3-Blocking Antibody Combination, Opduala MD Bureau20 March 2022 2:30 PM ISTThe trial met its primary endpoint, progression-free survival, and Opdualag more than doubled the median PFS when compared to nivolumab monotherapy,...
Bristol Myers Squibb Nivolumab marketing approval to be revoked for hepatocellular carcinoma: CDSCO panel Dr. Divya Colin14 March 2022 6:30 PM ISTNew Delhi: In a major setback for Bristol Myers Squibb, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO)...
USFDA accepts Bristol Myers Squibb's Application for Opdivo MD Bureau2 March 2022 12:10 PM ISTThe FDA granted the application Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 13, 2022.
